{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:15:00Z","timestamp":1788542100176,"version":"build-2803163510"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA033211"],"award-info":[{"award-number":["R25DA033211"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Addict"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1111\/ajad.12553","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T16:03:09Z","timestamp":1493913789000},"page":"572-580","source":"Crossref","is-referenced-by-count":85,"title":["Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-1490","authenticated-orcid":false,"given":"Ajay","family":"Manhapra","sequence":"first","affiliation":[{"name":"VA New England Mental Illness Research and Education Center; West Haven Connecticut"},{"name":"Department of Psychiatry; Yale School of Medicine; New Haven Connecticut"},{"name":"Department of Internal Medicine; Yale Medical School; New Haven Connecticut"},{"name":"VA Hampton Medical Center; Hampton Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene","family":"Petrakis","sequence":"additional","affiliation":[{"name":"VA New England Mental Illness Research and Education Center; West Haven Connecticut"},{"name":"Department of Psychiatry; Yale School of Medicine; New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rosenheck","sequence":"additional","affiliation":[{"name":"VA New England Mental Illness Research and Education Center; West Haven Connecticut"},{"name":"Department of Psychiatry; Yale School of Medicine; New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"key":"10.1111\/ajad.12553-BIB0001|ajad12553-cit-0001","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"key":"10.1111\/ajad.12553-BIB0002|ajad12553-cit-0002","first-page":"1936","article-title":"Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction","volume":"280","author":"Nih","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/ajad.12553-BIB0003|ajad12553-cit-0003","unstructured":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction"},{"key":"10.1111\/ajad.12553-BIB0004|ajad12553-cit-0004","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/add.12865","article-title":"Commentary on Burns et al. (2015): Retention in buprenorphine treatment","volume":"110","author":"Saxon","year":"2015","journal-title":"Addiction"},{"key":"10.1111\/ajad.12553-BIB0005|ajad12553-cit-0005","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"key":"10.1111\/ajad.12553-BIB0006|ajad12553-cit-0006","unstructured":"Medication-assisted treatment for opioid addiction in Opioid Treatment Programs"},{"key":"10.1111\/ajad.12553-BIB0007|ajad12553-cit-0007","unstructured":"Results from the 2013 national survey on drug use and health: Summary of national findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863"},{"key":"10.1111\/ajad.12553-BIB0008|ajad12553-cit-0008","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1111\/ajad.12553-BIB0009|ajad12553-cit-0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jsat.2013.10.006","article-title":"From methadone to buprenorphine: Changes during a 10 year period within a national opioid maintenance treatment programme","volume":"46","author":"Riksheim","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0010|ajad12553-cit-0010","unstructured":""},{"key":"10.1111\/ajad.12553-BIB0011|ajad12553-cit-0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajad.12174","article-title":"Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013","volume":"24","author":"Turner","year":"2014","journal-title":"Am J Addict"},{"key":"10.1111\/ajad.12553-BIB0012|ajad12553-cit-0012","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","article-title":"A call for evidence-based medical treatment of opioid dependence in the United States and Canada","volume":"32","author":"Nosyk","year":"2013","journal-title":"Health Aff"},{"key":"10.1111\/ajad.12553-BIB0013|ajad12553-cit-0013","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2000","journal-title":"Cochrane Library"},{"key":"10.1111\/ajad.12553-BIB0014|ajad12553-cit-0014","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3111\/13696998.2014.925463","article-title":"Persistence and healthcare utilization associated with the use of buprenorphine\/naloxone film and tablet formulation therapy in adults with opioid dependence","volume":"17","author":"Clay","year":"2014","journal-title":"J Med Econ"},{"key":"10.1111\/ajad.12553-BIB0015|ajad12553-cit-0015","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Associations between trajectories of buprenorphine treatment and emergency department and inpatient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"key":"10.1111\/ajad.12553-BIB0016|ajad12553-cit-0016","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"J Addict Dis"},{"key":"10.1111\/ajad.12553-BIB0017|ajad12553-cit-0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"key":"10.1111\/ajad.12553-BIB0018|ajad12553-cit-0018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3810\/pgm.2014.09.2805","article-title":"Analysis of buprenorphine\/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: A retrospective study of US public and private health care claims","volume":"126","author":"Khemiri","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1111\/ajad.12553-BIB0019|ajad12553-cit-0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7205\/MILMED-D-12-00131","article-title":"Unmet need for treatment of substance use disorders and serious psychological distress among veterans: A nationwide analysis using the NSDUH","volume":"178","author":"Golub","year":"2013","journal-title":"Mil Med"},{"key":"10.1111\/ajad.12553-BIB0020|ajad12553-cit-0020","first-page":"48","article-title":"Models for implementing buprenorphine treatment in the VHA","volume":"26","author":"Gordon","year":"2009","journal-title":"Federal Pract"},{"key":"10.1111\/ajad.12553-BIB0021|ajad12553-cit-0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the veterans health administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychol Addict Behav"},{"key":"10.1111\/ajad.12553-BIB0022|ajad12553-cit-0022","unstructured":"Stanton A. Rockville, MD: WESTAT 2006"},{"key":"10.1111\/ajad.12553-BIB0023|ajad12553-cit-0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1111\/ajad.12553-BIB0024|ajad12553-cit-0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jagp.2013.10.007","article-title":"Increased risk among older veterans of prescribing psychotropic medication in the absence of psychiatric diagnoses","volume":"22","author":"Wiechers","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1111\/ajad.12553-BIB0025|ajad12553-cit-0025","doi-asserted-by":"crossref","unstructured":"Ferguson CJ Professional Psychology: Research and Practice 2009 40 532 538","DOI":"10.1037\/a0015808"},{"key":"10.1111\/ajad.12553-BIB0026|ajad12553-cit-0026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/ajad.12553-BIB0027|ajad12553-cit-0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","article-title":"Long-term treatment with buprenorphine\/naloxone in primary care: Results at 2-5 years","volume":"17","author":"Fiellin","year":"2008","journal-title":"Am J Addict"},{"key":"10.1111\/ajad.12553-BIB0028|ajad12553-cit-0028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2012.12.008","article-title":"Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes","volume":"131","author":"Haddad","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0029|ajad12553-cit-0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.drugalcdep.2009.07.013","article-title":"Long-term outcomes of office-based buprenorphine\/naloxone maintenance therapy","volume":"106","author":"Parran","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0030|ajad12553-cit-0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year","volume":"37","author":"Soeffing","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0031|ajad12553-cit-0031","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine five-Year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1111\/ajad.12553-BIB0032|ajad12553-cit-0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the massachusetts collaborative care model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0033|ajad12553-cit-0033","unstructured":"The N-SSATS Report: Substance abuse treatment facilities operated by the Department of Veterans Affairs (November 11, 2009)"},{"key":"10.1111\/ajad.12553-BIB0034|ajad12553-cit-0034","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0035|ajad12553-cit-0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs methadone for opioid use disorder nationally in the Veterans Health Administration","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0036|ajad12553-cit-0036","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: Patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"J Subs Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0037|ajad12553-cit-0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2012.08.027","article-title":"A randomized trial of intensive outpatient (IOP) vs standard outpatient (OP) buprenorphine treatment for African Americans","volume":"128","author":"Mitchell","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0038|ajad12553-cit-0038","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsat.2006.03.013","article-title":"Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors","volume":"30","author":"Knudsen","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0039|ajad12553-cit-0039","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drugalcdep.2006.08.013","article-title":"The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters","volume":"87","author":"Knudsen","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0040|ajad12553-cit-0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","article-title":"Buprenorphine diffusion: The attitudes of substance abuse treatment counselors","volume":"29","author":"Knudsen","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/ajad.12553-BIB0041|ajad12553-cit-0041","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/08897077.2014.991469","article-title":"Adherence to buprenorphine treatment guidelines in a medicaid program","volume":"36","author":"Baxter","year":"2015","journal-title":"Subst Abuse"},{"key":"10.1111\/ajad.12553-BIB0042|ajad12553-cit-0042","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.drugalcdep.2011.10.004","article-title":"Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors","volume":"122","author":"Oliva","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/ajad.12553-BIB0043|ajad12553-cit-0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09595230500170241","article-title":"From opioid maintenance to abstinence: A literature review","volume":"24","author":"Kornor","year":"2005","journal-title":"Drug Alcohol Rev"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajad.12553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajad.12553\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T08:20:44Z","timestamp":1625300444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.12553"}},"subtitle":["3-Year Buprenorphine Retention in OUD"],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1111\/ajad.12553","archive":["Portico"],"relation":{},"ISSN":["1055-0496"],"issn-type":[{"value":"1055-0496","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}